moma-313

MOMA-313 is a highly potent and selective oral small molecule inhibitor of DNA polymerase theta (Polθ) helicase, developed by MOMA Therapeutics for the treatment of solid tumors with homologous recombination repair deficiencies, such as those harboring BRCA2 mutations. Polθ is involved in the repair of DNA double-strand breaks via the microhomology-mediated end joining (TMEJ) pathway, which becomes critical in tumors deficient in homologous recombination. By inhibiting Polθ helicase activity, MOMA-313 impairs TMEJ repair and induces apoptosis specifically in HR-deficient tumor cells. Preclinical studies have shown that MOMA-313 synergizes with PARP inhibitors like olaparib to enhance DNA damage and antitumor activity. The drug is currently being evaluated as monotherapy and in combination with olaparib for patients with metastatic prostate cancer, breast cancer, pancreatic cancer, and other solid tumors characterized by defects in DNA repair genes[1][2][3][4][5][6][8].

Other names

MOMA 313MOMA313MOMA-313